LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TSHA
Taysha Gene Therapies, Inc.
There isn't enough reported data to score TSHA yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TSHA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
TSHA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TSHA PE Valuation
TSHA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TSHA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| High |
Analysts expect TSHA's losses to grow, with revenue declining.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TSHA on earnings quality, reporting a profit while its opponent remains loss making.
TSHA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.43 | -$0.10 |
| Q2 2026 | -$0.42 | -$0.08 |
| Q1 2026 | -$0.38 | -$0.04 |
| Q4 2025 | -$0.34 | +$0.02 |
| Q3 2025 | -$0.33 | -197% |
| Q2 2025 | -$0.34 | +$0.15 |
| Q1 2025 | -$0.34 | +$0.44 |
| Q4 2024 | -$0.36 | +$0.60 |
TSHA is still losing money, but far less than before: $0.43 per share over the past year, against $5.08 at its worst in early 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TSHA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
TSHA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.5M | +171% |
| Q2 2025 | $2M | +79% |
| Q1 2025 | $2.3M | -33% |
| Q4 2024 | $2M | -44% |
| Q3 2024 | $1.8M | -62% |
| Q2 2024 | $1.1M | -54% |
| Q1 2024 | $3.4M | -28% |
TSHA's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -516% | +470 points |
| Q2 2025 | -1347% | +568 points |
| Q1 2025 | -931% | -217 points |
| Q4 2024 | -986% | -535 points |
| Q3 2024 | -1448% | -1106 points |
| Q2 2024 | -1915% | -939 points |
| Q1 2024 | -713% | -361 points |
| Q4 2023 | -451% | N/A |
TSHA's operating margin was −516% last quarter, up 932 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TSHA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TSHA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.4M | -$9.1M |
| Q1 2026 | -$40.9M | -$18.9M |
| Q4 2025 | -$27M | -$8.7M |
| Q3 2025 | -$24.3M | -$2.6M |
| Q1 2025 | -$22M | -$2.1M |
| Q4 2024 | -$18.3M | -$2.2M |
| Q3 2024 | -$21.7M | -$3.7M |
| Q2 2024 | -$21.7M | -$3M |
TSHA has burned cash in almost every quarter: −$142M over the past year, against −$86M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TSHA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TSHA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +37.1M shares |
| 1 year | +15% | +52.8M shares |
| 3 years | +532% | +342M shares |
| 5 years | +998% | +369M shares |
| Available history | +2577% | +391M shares |
TSHA has 406M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TSHA Net Leverage
TSHA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TSHA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 23.3 | Neutral |
TSHA's weekly RSI is 41 (neutral) and its Stochastic is 23 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TSHA PE vs Healthcare Sector
| Metric | TSHA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TSHA has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TSHA on trend strength, trading above more of its moving averages.
TSHA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.25 | 0.9% below |
| 20 week MA | $5.21 | 19% below |
| 50 week MA | $5.25 | 20% below |
| 100 week MA | $3.94 | 6.9% above |
| 200 week MA | $2.92 | 44% above |
TSHA has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 44% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TSHA on returns for 2026, with the stronger performance.
TSHA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.5 | $27.2 | +11% |
| 2021 | $27.2 | $12.8 | -53% |
| 2022 | $12.8 | $2.08 | -84% |
| 2023 | $2.08 | $1.77 | -15% |
| 2024 | $1.77 | $1.75 | -1.1% |
| 2025 | $1.75 | $5.83 | +233% |
| 2026 YTD | $5.83 | $4.21 | -28% |
TSHA's yearly returns have swung widely, from +233% in 2025 to −84% in 2022. It's down 28% so far in 2026.